Synopsis: Shares of Panacea Biotec Ltd gained in Wednesday’s session after the company received an award notification from the Pan American Health Organization (PAHO), the Regional Office of the World Health Organization (WHO), for the supply of vaccines worth Rs. 41 crore over 2026-2027.
A small-cap pharmaceutical stock saw buying interest in today’s trade after securing a fresh international vaccine supply award, strengthening its export pipeline and order visibility.
Panacea Biotec Ltd, with a market capitalisation of Rs. 2,449.42 crore, opened at Rs. 407.05 on the BSE against its previous close of Rs. 396.40. The stock touched an intraday high of Rs. 407.05, marking an increase of 2.69 percent from the previous close.
What’s the News?
Panacea Biotec Ltd announced that it has received an award notification from the Pan American Health Organization (PAHO), the Regional Office of the World Health Organization, under a long-term agreement for the supply of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine (Pentavalent) – Liquid (single dose), branded as Easyfive-TT.
Easyfive-TT is a five-in-one vaccine administered to infants and young children. It offers protection against five serious diseases, Diphtheria, Haemophilus influenzae type b, Hepatitis B, Pertussis, and Tetanus, by strengthening the immune system and stimulating the body to produce protective antibodies against these infections.
The total award is valued at approximately USD 4.75 million (around Rs. 41 crore) for the supply of the Easyfive-TT vaccine during calendar years 2026 and 2027. The vaccine will be supplied to PAHO as per their requirements under the long-term arrangement.
Financial Snapshot – Q1FY26
Quarter-on-Quarter (QoQ): In Q1FY26, Panacea Biotec posted robust sequential improvement in performance. Sales rose from Rs. 132.53 crore in Q4FY25 to Rs. 166.70 crore, registering an increase of 25.8 percent. Operating loss narrowed sharply from Rs. 26.88 crore to Rs. 1.18 crore. Profit before tax turned positive, improving from a marginal loss of Rs. 0.04 crore to a profit of Rs. 6.56 crore. Net profit also rose from a loss of Rs. 1.99 crore to a profit of Rs. 3.96 crore.
Year-on-Year (YoY): On an annual comparison, sales grew from Rs. 115.72 crore in Q1FY25 to Rs. 166.70 crore in Q1FY26, marking a 44 percent increase. Operating loss reduced significantly from Rs. 13.99 crore to Rs. 1.18 crore. Profit before tax improved from a loss of Rs. 17.05 crore to a profit of Rs. 6.56 crore, while net profit rose from a loss of Rs. 15.88 crore to a profit of Rs. 3.96 crore.
About the Company
Panacea Biotec Ltd is one of India’s leading research-driven biotechnology companies engaged in the research, development, manufacturing, and marketing of vaccines and pharmaceutical formulations. The company supplies its products across India and global markets, catering to both private and institutional healthcare segments.
Written by Manan Gangwar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
